Activation of farnesoid X receptor upregulates binding immunoglobulin protein expression and alleviates diabetic nephropathy

Figure 3 Farnesoid X receptor regulates the effect of binding immunoglobulin protein on downstream endoplasmic reticulum stress related signaling molecules. A: Bar chart showing the expression levels of protein kinase R-like endoplasmic reticulum kinase (PERK) message RNA (mRNA) in different treatment groups, detected by quantitative real-time polymerase chain reaction (qRT-PCR); B: Western blot (WB) displays the expression levels of PERK protein in different treatment groups, and the bar chart shows the grayscale values of WB bands; C: Bar chart showing the expression levels of inositol-requiring enzyme 1 (IRE1) mRNA in different treatment groups, detected by qRT-PCR; D: WB displays the expression levels of the IRE1 protein in different treatment groups, with the bar chart showing the grayscale values of WB bands; E: Bar chart showing the expression levels of activating transcription factor 6 (ATF6) mRNA in different treatment groups, detected by qRT-PCR; F: WB displays the expression levels of the ATF6 protein in different treatment groups, with the bar chart showing the grayscale values of WB bands. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ^dP < 0.0001. HG: High glucose; LG: Low glucose; INT-747: Obeticholic acid; BiP: Binding immunoglobulin protein; Gugg: Guggulsterones; siRNA: Small interfering RNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; PERK: Protein kinase R-like endoplasmic reticulum kinase; IRE1: Inositol-requiring enzyme 1; ATF6: Activating transcription factor 6.